Cure­Vac posts an up­beat take on in­ter­im PhI Covid-19 vac­cine re­sults, with a piv­otal study loom­ing. But you'll have to wait on da­ta

Cure­Vac $CVAC trails its com­peti­tors in the Covid-19 vac­cine race, but the Ger­man biotech is keep­ing up with the pace.

The com­pa­ny re­port­ed in­ter­im re­sults of a Phase I study Mon­day, say­ing its ex­per­i­men­tal vac­cine in­duced an im­mune re­sponse in hu­mans and ap­peared to gen­er­ate T cells against SARS-CoV-2. Full da­ta are com­ing lat­er, but Cure­Vac ex­ecs say they saw enough ev­i­dence to take the high­est dose test­ed — 12 μg — in­to a Phase IIb/III be­fore the end of the year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER